This review assessed the effectiveness of drug therapy on groups of symptoms in patients with severe personality disorder, concluding that mood stabilisers deserved greater consideration, but caution was needed. There were some methodological limitations and the authors' recommendation for caution in interpreting the findings was appropriate.
Three reviewers extracted the mean scores at the beginning and end of treatment and extracted or calculated their associated standard deviations. For each study, the standardised mean difference between the active treatment and placebo was calculated using Cohen's d. The trial authors were contacted for further information, where necessary and discrepancies were resolved by consensus.
Methods of synthesis
A fixed-effect model, or a random-effects model where there was evidence of statistical heterogeneity, was used to calculate the overall standardised mean differences, corrected for small sample sizes, and their 95% confidence intervals, grouped by type of pharmacotherapy. Statistical heterogeneity was assessed using the Cochran Q and the I 2 tests.
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Results of the review
Thirty-two relevant RCTs were identified and 21 (19 publications) were included in the meta-analyses (n=837 patients; range 16 to 72). The dropout rates ranged from 3% to 63%.
Antipsychotics: (six RCTs, n=307) Compared with placebo, antipsychotics had a statistically significant greater effect on cognitive-perceptual symptoms (SMD 0.56, 95% CI 0.05 to 1.07; five RCTs), on the affective dysregulation symptom of anger (SMD 0.69, 95% CI 0.16 to 1.22; four RCTs), and global functioning (SMD 0.37, 95% CI 0.12 to 0.62; five RCTs), but there was evidence of statistical heterogeneity for all comparisons (I 2 =70% or 79%). There were no statistically significant differences for impulsive-behavioural dyscontrol symptoms and affective dysregulation symptoms of depressed mood, anxiety, and mood lability.
Antidepressants: (seven RCTs, n=278) Antidepressants were statistically significantly more effective than placebo on the affective dysregulation symptoms of anxiety (SMD 0.30, 95% CI 0.02 to 0.59; five RCTs) and anger (SMD 0.34, 95% CI 0.03 to 0.65; four RCTs). There was no evidence of statistical heterogeneity (I 2 =0%), for either comparison. No statistically significant differences were found in global functioning, cognitive-perceptual symptoms, impulsivebehavioural dyscontrol symptoms, and the affective dysregulation symptoms of depressed mood and mood lability.
Mood stabilisers: (eight RCTs, n=252) Mood stabilisers were statistically significantly more effective than placebo in impulsive-behavioural dyscontrol symptoms (SMD 1.51, 95% CI 0.42 to 2.59; I 2 =90%; six RCTs), affective dysregulation symptoms of depressed mood (SMD 0.55, 95% CI 0.21 to 0.90; I 2 =0%; five RCTs), anxiety (SMD 0.80, 95% CI 0.38 to 1.21; I 2 =0%; three RCTs), and anger (SMD 1.33, 95% CI 0.43 to 2.22; I
